.jpg "Intercept Pharma (NASDAQ: ICPT)")
Chardan Capital analyst Michael Morabito reiterated a Buy rating on Intercept Pharma (ICPT) today and set a price target of $145.00. The company’s shares closed last Tuesday at $91.50.
Morabito has an average return of 16.1% when recommending Intercept Pharma.
According to TipRanks.com, Morabito is ranked #4269 out of 6562 analysts.
Currently, the analyst consensus on Intercept Pharma is a Moderate Buy with an average price target of $147.54, representing a 61.0% upside. In a report issued on May 1, Wedbush also maintained a Buy rating on the stock with a $257.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $125.00 and a one-year low of $47.57. Currently, Intercept Pharma has an average volume of 593.1K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Intercept Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.
